Bristol-Myers Squibb
 
2Q Revenues: $4.4 billion (-18%)

2Q Earnings: $808 million (-38%)

YTD Revenues: $9.7 billion (-7%)

YTD Earnings: $2.3 billion (-14%)

Comments: U.S. sales were down 27% to $2.6 billion in the quarter due to patent expirations for Avapro/Avalide (-40%) and Plavix (-33%). Abilify sales were $711 million (+1%). Reyataz sales were $406 million (+3%). Sustiva Franchise sales were $388 million (+5%). Onglyza/Kombiglyze sales were up 54% to $174 million, Baraclude sales were up 22% to $357 million, Orencia sales were up 27% to $290 million, Sprycel sales were up 26% to $244 million and Yervoy sales were $162 million (+71%).